Genmab A (GMAB) Income towards Parent Company (2018 - 2026)
Genmab A (GMAB) posted Income towards Parent Company of $5.7 billion for Q1 2026, down 1.2% on a QoQ basis from $5.8 billion in Q3 2025, and up 7.29% year-over-year from $5.3 billion in Q1 2025.
Genmab A (GMAB) Income towards Parent Company (2018 - 2026) Analysis & Trends
Genmab A's Income towards Parent Company history runs 6 years deep, the most recent figure standing at $5.7 billion for Q1 2026.
- Quarterly Income towards Parent Company rose 7.29% year-over-year to $5.7 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 billion (up 1.08% YoY) and the FY2025 annual result came in at $963.0 million, down 81.25% from the prior year.
- Income towards Parent Company was $5.7 billion for Q1 2026 at Genmab A, down from $5.8 billion in the prior quarter.
- Across five years, Income towards Parent Company topped out at $5.8 billion in Q3 2025 and bottomed at $556.0 million in Q2 2024.
- A 3-year average of $3.6 billion and a median of $4.8 billion in 2024 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2025 — Income towards Parent Company advanced 19.99% — and 2026, when it increased 7.29%.
- Genmab A's Income towards Parent Company stood at $1.3 billion in 2024, then surged by 333.71% to $5.8 billion in 2025, then retreated by 1.2% to $5.7 billion in 2026.
- Business Quant data shows GMAB's Income towards Parent Company at $5.7 billion in Q1 2026, $5.8 billion in Q3 2025, and $667.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Genmab A | 1.87 Bn | 349.77 Mn | 831.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.68 Bn |
| Sep 30, 2025 | 5.75 Bn |
| Jun 30, 2025 | 667.00 Mn |
| Mar 31, 2025 | 5.30 Bn |
| Dec 31, 2024 | 1.33 Bn |
| Sep 30, 2024 | 4.79 Bn |
| Jun 30, 2024 | 556.00 Mn |
| Mar 31, 2024 | 4.71 Bn |
| Sep 30, 2020 | 284.26 |
| Dec 31, 2019 | 192.57 |
| Sep 30, 2019 | 699.28 Mn |
| Dec 31, 2018 | 115.13 |